Relay Therapeutics, Inc. (RLAY)

NASDAQ: RLAY · IEX Real-Time Price · USD
8.30
+0.14 (1.72%)
At close: Mar 28, 2024, 4:00 PM
8.40
+0.10 (1.20%)
After-hours: Mar 28, 2024, 5:09 PM EDT

Company Description

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company.

It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications.

The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors.

In addition, it has collaboration and license agreements with D. E.

Shaw Research, LLC to research certain biological targets through the use of D. E.

Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971.

The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015.

Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Relay Therapeutics, Inc.
Relay Therapeutics logo
Country United States
Founded 2015
IPO Date Jul 16, 2020
Industry Biotechnology
Sector Healthcare
Employees 323
CEO Dr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBS

Contact Details

Address:
399 Binney Street, 2nd Floor
Cambridge, Massachusetts 02139
United States
Phone 617-370-8837
Website relaytx.com

Stock Details

Ticker Symbol RLAY
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $20.00
CIK Code 0001812364
CUSIP Number 75943R102
ISIN Number US75943R1023
SIC Code 2836

Key Executives

Name Position
Alexis A. Borisy A.M. Co-Founder and Independent Chairman
Dr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBS Chief Executive Officer, President and Director
Dr. Mark Murcko Ph.D. Co-Founder and Director
Thomas Catinazzo Chief Financial Officer
Brian R. Adams J.D. Chief Legal Officer and Secretary
Dr. Donald A. Bergstrom M.D., Ph.D. President of Research and Development
Peter Rahmer Chief Corporate Development Officer
Dr. Deborah Palestrant M.B.A., Ph.D. Vice President of Corporate Development and Strategy
Jim Watters Ph.D. Chief Scientific Officer of Late Research
Dr. Beni B. Wolf M.D., Ph.D. Chief Medical Officer and Head of Precision Medicine

Latest SEC Filings

Date Type Title
Feb 22, 2024 S-8 Securities to be offered to employees in employee benefit plans
Feb 22, 2024 10-K Annual Report
Feb 22, 2024 8-K Current Report
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Feb 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jan 26, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jan 23, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jan 10, 2024 424B7 Filing
Jan 10, 2024 D Notice of Exempt Offering of Securities